News

   

Asarina Pharma: Journal of Neuroendocrinology publishes preclinical data on effective Tourette syndrome therapy with no side effects

Stockholm, June 12 2019: A new paper in the Journal of Neuroendocrinology shows how Asarina Pharma’s compound Sepranolone reduced tics in an animal model of Tourette syndrome as effectively as current first-line treatment Haldol—without inducing any motor side effects.

Full PDF
   

Premenstrual Dysphoric Disorder recognized in new WHO International Classification of Diseases ICD-11

Stockholm, June 11, 2019: Premenstrual dysphoric disorder (PMDD) has been given its own classification code and for the first time classified clearly as a gynaecological, not mental, disease in the WHO’s new International Classification of Diseases, ICD-11. “This is a crucial step forward for future diagnosis, treatment and reimbursement of our lead indication” says CEO…

Full PDF
   

PMS & PMDD in spotlight at Gothenburg event for International Menstrual Hygiene Day

(Stockholm May 23, 2019) Valuable knowledge about PMS & PMDD will be shared at the University of Gothenburg on May 28 at a public evening of talks, lectures and Q&A. Prof Torbjörn Bäckström, PMDD research pioneer and Asarina Pharma CSO, will speak about the science and treatment of PMDD.

Full PDF
   

Decisions from Annual General Meeting of Asarina Pharma, 8 May 2019

(Stockholm May 8, 2019) On 8 May 2019, the Annual General Meeting (”AGM”) of Asarina Pharma AB (publ) was held in Stockholm. Read below for a summary of the decisions made.

Full PDF
   

Asarina Pharma Clinical Trial featured on BBC

(Stockholm April 23 2019) With approx. 4 million listeners, on April 17 BBC Radio’s iconic programme ‘Woman’s Hour’ highlighted the clinical trial of a new treatment for PMDD, the severest form of PMS. The trial is being carried out by Swedish company Asarina Pharma

Full PDF